- Home
- NERV vs DFDV Comparison
NERV vs DFDV Comparison
Compare NERV & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NERV | DFDV |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.1M | 219.8M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NERV | DFDV |
|---|---|---|
| Price | $4.45 | $5.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $45.00 |
| AVG Volume (30 Days) | 74.6K | ★ 1.8M |
| Earning Date | 02-24-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.13 |
| Revenue | N/A | ★ $7,526,660.00 |
| Revenue This Year | N/A | $343.83 |
| Revenue Next Year | N/A | $104.68 |
| P/E Ratio | ★ N/A | $1.47 |
| Revenue Growth | N/A | ★ 313.28 |
| 52 Week Low | $1.15 | $0.53 |
| 52 Week High | $12.46 | $53.88 |
Technical Indicators
Market Signals| Indicator | NERV | DFDV |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 43.93 |
| Support Level | $3.75 | $5.51 |
| Resistance Level | $4.65 | $8.45 |
| Average True Range (ATR) | 0.35 | 0.67 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 64.71 | 12.24 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About DFDV DeFi Development Corp.
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.